The pulmonary arterial hypertension treatment market has witnessed a significant transformation in recent years, driven by advancements in medical research and increasing awareness about rare ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

Insmed achieved positive phase 2b results for TPIP in PAH. Click here to find out why INSM stock is a Strong Buy.

June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the "AGM") ...

Hypertension, a global health crisis affecting over a billion adults, significantly elevates the risk of stroke, aneurysm, ...

Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

The ZENITH study found that in high-risk PAH, add-on sotatercept was tied to lower risk for death from any cause, lung ...

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor Contact: David ...

Panelists discuss how early detection barriers include nonspecific symptoms like progressive dyspnea that are often ...

In this situation the LAD has allowed a reduction in inotrope support, an improvement in gas exchange parameters, optimization of ventilatory support requirements and extubation in selected cases.